Journal article 434 views 57 downloads
Incident atrial fibrillation and adverse clinical outcomes during extended follow-up of participants recruited to the remote heart rhythm sampling using the AliveCor heart monitor to screen for atrial fibrillation: the REHEARSE-AF...
European Heart Journal Open, Volume: 3, Issue: 3
Swansea University Authors:
Libby Ellins , Daniel Harris, Ashley Akbari
, Ceri Phillips, Michael Gravenor
, Julian Halcox
-
PDF | Version of Record
This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (https://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
Download (416.61KB)
DOI (Published version): 10.1093/ehjopen/oead047
Abstract
Aims: Atrial fibrillation (AF) is an important risk factor for stroke, which is commonly asymptomatic, particularly in older patients, and often undetected until cardiovascular events occur. Development of novel technology has helped to improve detection of AF. However, the longer-term benefit of sy...
Published in: | European Heart Journal Open |
---|---|
ISSN: | 2752-4191 |
Published: |
Oxford University Press (OUP)
2023
|
Online Access: |
Check full text
|
URI: | https://cronfa.swan.ac.uk/Record/cronfa63344 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
first_indexed |
2023-05-04T09:24:38Z |
---|---|
last_indexed |
2023-05-04T09:24:38Z |
id |
cronfa63344 |
recordtype |
SURis |
fullrecord |
<?xml version="1.0" encoding="utf-8"?><rfc1807 xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xsd="http://www.w3.org/2001/XMLSchema"><bib-version>v2</bib-version><id>63344</id><entry>2023-05-04</entry><title>Incident atrial fibrillation and adverse clinical outcomes during extended follow-up of participants recruited to the remote heart rhythm sampling using the AliveCor heart monitor to screen for atrial fibrillation: the REHEARSE-AF study</title><swanseaauthors><author><sid>553ce2abe05a6396e7dd6eadb6b90a6d</sid><ORCID>0000-0001-5164-6416</ORCID><firstname>Libby</firstname><surname>Ellins</surname><name>Libby Ellins</name><active>true</active><ethesisStudent>false</ethesisStudent></author><author><sid>e60c9c73b645f0e8033ae26fa8e634b8</sid><firstname>Daniel</firstname><surname>Harris</surname><name>Daniel Harris</name><active>true</active><ethesisStudent>false</ethesisStudent></author><author><sid>aa1b025ec0243f708bb5eb0a93d6fb52</sid><ORCID>0000-0003-0814-0801</ORCID><firstname>Ashley</firstname><surname>Akbari</surname><name>Ashley Akbari</name><active>true</active><ethesisStudent>false</ethesisStudent></author><author><sid>932c7a406ab4b6e4a881d422ca03c289</sid><firstname>Ceri</firstname><surname>Phillips</surname><name>Ceri Phillips</name><active>true</active><ethesisStudent>false</ethesisStudent></author><author><sid>70a544476ce62ba78502ce463c2500d6</sid><ORCID>0000-0003-0710-0947</ORCID><firstname>Michael</firstname><surname>Gravenor</surname><name>Michael Gravenor</name><active>true</active><ethesisStudent>false</ethesisStudent></author><author><sid>3676f695eeda169d0f8c618adf27c04b</sid><ORCID>0000-0001-6926-2947</ORCID><firstname>Julian</firstname><surname>Halcox</surname><name>Julian Halcox</name><active>true</active><ethesisStudent>false</ethesisStudent></author></swanseaauthors><date>2023-05-04</date><deptcode>HDAT</deptcode><abstract>Aims: Atrial fibrillation (AF) is an important risk factor for stroke, which is commonly asymptomatic, particularly in older patients, and often undetected until cardiovascular events occur. Development of novel technology has helped to improve detection of AF. However, the longer-term benefit of systematic electrocardiogram (ECG) screening on cardiovascular outcomes is unclear. Methods and results: In the original REHEARSE-AF study, patients were randomized to twice-weekly portable electrocardiogram (iECG) assessment or routine care. After discontinuing the trial portable iECG assessment, electronic health record data sources provided longer-term follow-up analysis. Cox regression was used to provide unadjusted and adjusted hazard ratios (HR) [95% confidence intervals (CI)] for clinical diagnosis, events, and anticoagulant prescriptions during the follow-up period. Over the median 4.2-year follow-up, although a greater number of patients were diagnosed with AF in the original iECG group (43 vs. 31), this was not significant (HR 1.37, 95% CI 0.86–2.19). No differences were seen in the number of strokes/systemic embolisms or deaths between the two groups (HR 0.92, 95% CI 0.54–1.54; HR 1.07, 95% CI 0.66–1.73). Findings were similar when restricted to those with CHADS-VASc ≥ 4. Conclusion: A 1-year period of home-based, twice-weekly screening for AF increased diagnoses of AF for the screening period but did not lead to increased diagnoses of AF or a reduction in cardiovascular-related events or all-cause death over a median of 4.2 years, even in those at highest risk of AF. These results suggest that benefits of regular ECG screening over a 1-year period are not maintained after cessation of the screening protocol.</abstract><type>Journal Article</type><journal>European Heart Journal Open</journal><volume>3</volume><journalNumber>3</journalNumber><paginationStart/><paginationEnd/><publisher>Oxford University Press (OUP)</publisher><placeOfPublication/><isbnPrint/><isbnElectronic/><issnPrint/><issnElectronic>2752-4191</issnElectronic><keywords>Atrial fibrillation, Electrocardiography, Mass screening, Preventive medicine, Stroke</keywords><publishedDay>2</publishedDay><publishedMonth>5</publishedMonth><publishedYear>2023</publishedYear><publishedDate>2023-05-02</publishedDate><doi>10.1093/ehjopen/oead047</doi><url>http://dx.doi.org/10.1093/ehjopen/oead047</url><notes/><college>COLLEGE NANME</college><department>Health Data Science</department><CollegeCode>COLLEGE CODE</CollegeCode><DepartmentCode>HDAT</DepartmentCode><institution>Swansea University</institution><apcterm>SU Library paid the OA fee (TA Institutional Deal)</apcterm><funders>Swansea University</funders><projectreference/><lastEdited>2023-07-24T12:07:01.2977519</lastEdited><Created>2023-05-04T09:46:54.6808423</Created><path><level id="1">Faculty of Medicine, Health and Life Sciences</level><level id="2">Swansea University Medical School - Health Data Science</level></path><authors><author><firstname>Libby</firstname><surname>Ellins</surname><orcid>0000-0001-5164-6416</orcid><order>1</order></author><author><firstname>Kathie</firstname><surname>Wareham</surname><order>2</order></author><author><firstname>Daniel</firstname><surname>Harris</surname><order>3</order></author><author><firstname>Matthew</firstname><surname>Hanney</surname><order>4</order></author><author><firstname>Ashley</firstname><surname>Akbari</surname><orcid>0000-0003-0814-0801</orcid><order>5</order></author><author><firstname>Mark</firstname><surname>Gilmore</surname><order>6</order></author><author><firstname>James P</firstname><surname>Barry</surname><order>7</order></author><author><firstname>Ceri</firstname><surname>Phillips</surname><order>8</order></author><author><firstname>Michael</firstname><surname>Gravenor</surname><orcid>0000-0003-0710-0947</orcid><order>9</order></author><author><firstname>Julian</firstname><surname>Halcox</surname><orcid>0000-0001-6926-2947</orcid><order>10</order></author></authors><documents><document><filename>63344__27607__5f757f6a719544b282231aaef63be74b.pdf</filename><originalFilename>63344.pdf</originalFilename><uploaded>2023-05-24T16:37:02.4343813</uploaded><type>Output</type><contentLength>426607</contentLength><contentType>application/pdf</contentType><version>Version of Record</version><cronfaStatus>true</cronfaStatus><documentNotes>This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (https://creativecommons.org/licenses/by-nc/4.0/), which permits
non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com</documentNotes><copyrightCorrect>true</copyrightCorrect><language>eng</language><licence>https://creativecommons.org/licenses/by-nc/4.0/</licence></document></documents><OutputDurs/></rfc1807> |
spelling |
v2 63344 2023-05-04 Incident atrial fibrillation and adverse clinical outcomes during extended follow-up of participants recruited to the remote heart rhythm sampling using the AliveCor heart monitor to screen for atrial fibrillation: the REHEARSE-AF study 553ce2abe05a6396e7dd6eadb6b90a6d 0000-0001-5164-6416 Libby Ellins Libby Ellins true false e60c9c73b645f0e8033ae26fa8e634b8 Daniel Harris Daniel Harris true false aa1b025ec0243f708bb5eb0a93d6fb52 0000-0003-0814-0801 Ashley Akbari Ashley Akbari true false 932c7a406ab4b6e4a881d422ca03c289 Ceri Phillips Ceri Phillips true false 70a544476ce62ba78502ce463c2500d6 0000-0003-0710-0947 Michael Gravenor Michael Gravenor true false 3676f695eeda169d0f8c618adf27c04b 0000-0001-6926-2947 Julian Halcox Julian Halcox true false 2023-05-04 HDAT Aims: Atrial fibrillation (AF) is an important risk factor for stroke, which is commonly asymptomatic, particularly in older patients, and often undetected until cardiovascular events occur. Development of novel technology has helped to improve detection of AF. However, the longer-term benefit of systematic electrocardiogram (ECG) screening on cardiovascular outcomes is unclear. Methods and results: In the original REHEARSE-AF study, patients were randomized to twice-weekly portable electrocardiogram (iECG) assessment or routine care. After discontinuing the trial portable iECG assessment, electronic health record data sources provided longer-term follow-up analysis. Cox regression was used to provide unadjusted and adjusted hazard ratios (HR) [95% confidence intervals (CI)] for clinical diagnosis, events, and anticoagulant prescriptions during the follow-up period. Over the median 4.2-year follow-up, although a greater number of patients were diagnosed with AF in the original iECG group (43 vs. 31), this was not significant (HR 1.37, 95% CI 0.86–2.19). No differences were seen in the number of strokes/systemic embolisms or deaths between the two groups (HR 0.92, 95% CI 0.54–1.54; HR 1.07, 95% CI 0.66–1.73). Findings were similar when restricted to those with CHADS-VASc ≥ 4. Conclusion: A 1-year period of home-based, twice-weekly screening for AF increased diagnoses of AF for the screening period but did not lead to increased diagnoses of AF or a reduction in cardiovascular-related events or all-cause death over a median of 4.2 years, even in those at highest risk of AF. These results suggest that benefits of regular ECG screening over a 1-year period are not maintained after cessation of the screening protocol. Journal Article European Heart Journal Open 3 3 Oxford University Press (OUP) 2752-4191 Atrial fibrillation, Electrocardiography, Mass screening, Preventive medicine, Stroke 2 5 2023 2023-05-02 10.1093/ehjopen/oead047 http://dx.doi.org/10.1093/ehjopen/oead047 COLLEGE NANME Health Data Science COLLEGE CODE HDAT Swansea University SU Library paid the OA fee (TA Institutional Deal) Swansea University 2023-07-24T12:07:01.2977519 2023-05-04T09:46:54.6808423 Faculty of Medicine, Health and Life Sciences Swansea University Medical School - Health Data Science Libby Ellins 0000-0001-5164-6416 1 Kathie Wareham 2 Daniel Harris 3 Matthew Hanney 4 Ashley Akbari 0000-0003-0814-0801 5 Mark Gilmore 6 James P Barry 7 Ceri Phillips 8 Michael Gravenor 0000-0003-0710-0947 9 Julian Halcox 0000-0001-6926-2947 10 63344__27607__5f757f6a719544b282231aaef63be74b.pdf 63344.pdf 2023-05-24T16:37:02.4343813 Output 426607 application/pdf Version of Record true This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (https://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com true eng https://creativecommons.org/licenses/by-nc/4.0/ |
title |
Incident atrial fibrillation and adverse clinical outcomes during extended follow-up of participants recruited to the remote heart rhythm sampling using the AliveCor heart monitor to screen for atrial fibrillation: the REHEARSE-AF study |
spellingShingle |
Incident atrial fibrillation and adverse clinical outcomes during extended follow-up of participants recruited to the remote heart rhythm sampling using the AliveCor heart monitor to screen for atrial fibrillation: the REHEARSE-AF study Libby Ellins Daniel Harris Ashley Akbari Ceri Phillips Michael Gravenor Julian Halcox |
title_short |
Incident atrial fibrillation and adverse clinical outcomes during extended follow-up of participants recruited to the remote heart rhythm sampling using the AliveCor heart monitor to screen for atrial fibrillation: the REHEARSE-AF study |
title_full |
Incident atrial fibrillation and adverse clinical outcomes during extended follow-up of participants recruited to the remote heart rhythm sampling using the AliveCor heart monitor to screen for atrial fibrillation: the REHEARSE-AF study |
title_fullStr |
Incident atrial fibrillation and adverse clinical outcomes during extended follow-up of participants recruited to the remote heart rhythm sampling using the AliveCor heart monitor to screen for atrial fibrillation: the REHEARSE-AF study |
title_full_unstemmed |
Incident atrial fibrillation and adverse clinical outcomes during extended follow-up of participants recruited to the remote heart rhythm sampling using the AliveCor heart monitor to screen for atrial fibrillation: the REHEARSE-AF study |
title_sort |
Incident atrial fibrillation and adverse clinical outcomes during extended follow-up of participants recruited to the remote heart rhythm sampling using the AliveCor heart monitor to screen for atrial fibrillation: the REHEARSE-AF study |
author_id_str_mv |
553ce2abe05a6396e7dd6eadb6b90a6d e60c9c73b645f0e8033ae26fa8e634b8 aa1b025ec0243f708bb5eb0a93d6fb52 932c7a406ab4b6e4a881d422ca03c289 70a544476ce62ba78502ce463c2500d6 3676f695eeda169d0f8c618adf27c04b |
author_id_fullname_str_mv |
553ce2abe05a6396e7dd6eadb6b90a6d_***_Libby Ellins e60c9c73b645f0e8033ae26fa8e634b8_***_Daniel Harris aa1b025ec0243f708bb5eb0a93d6fb52_***_Ashley Akbari 932c7a406ab4b6e4a881d422ca03c289_***_Ceri Phillips 70a544476ce62ba78502ce463c2500d6_***_Michael Gravenor 3676f695eeda169d0f8c618adf27c04b_***_Julian Halcox |
author |
Libby Ellins Daniel Harris Ashley Akbari Ceri Phillips Michael Gravenor Julian Halcox |
author2 |
Libby Ellins Kathie Wareham Daniel Harris Matthew Hanney Ashley Akbari Mark Gilmore James P Barry Ceri Phillips Michael Gravenor Julian Halcox |
format |
Journal article |
container_title |
European Heart Journal Open |
container_volume |
3 |
container_issue |
3 |
publishDate |
2023 |
institution |
Swansea University |
issn |
2752-4191 |
doi_str_mv |
10.1093/ehjopen/oead047 |
publisher |
Oxford University Press (OUP) |
college_str |
Faculty of Medicine, Health and Life Sciences |
hierarchytype |
|
hierarchy_top_id |
facultyofmedicinehealthandlifesciences |
hierarchy_top_title |
Faculty of Medicine, Health and Life Sciences |
hierarchy_parent_id |
facultyofmedicinehealthandlifesciences |
hierarchy_parent_title |
Faculty of Medicine, Health and Life Sciences |
department_str |
Swansea University Medical School - Health Data Science{{{_:::_}}}Faculty of Medicine, Health and Life Sciences{{{_:::_}}}Swansea University Medical School - Health Data Science |
url |
http://dx.doi.org/10.1093/ehjopen/oead047 |
document_store_str |
1 |
active_str |
0 |
description |
Aims: Atrial fibrillation (AF) is an important risk factor for stroke, which is commonly asymptomatic, particularly in older patients, and often undetected until cardiovascular events occur. Development of novel technology has helped to improve detection of AF. However, the longer-term benefit of systematic electrocardiogram (ECG) screening on cardiovascular outcomes is unclear. Methods and results: In the original REHEARSE-AF study, patients were randomized to twice-weekly portable electrocardiogram (iECG) assessment or routine care. After discontinuing the trial portable iECG assessment, electronic health record data sources provided longer-term follow-up analysis. Cox regression was used to provide unadjusted and adjusted hazard ratios (HR) [95% confidence intervals (CI)] for clinical diagnosis, events, and anticoagulant prescriptions during the follow-up period. Over the median 4.2-year follow-up, although a greater number of patients were diagnosed with AF in the original iECG group (43 vs. 31), this was not significant (HR 1.37, 95% CI 0.86–2.19). No differences were seen in the number of strokes/systemic embolisms or deaths between the two groups (HR 0.92, 95% CI 0.54–1.54; HR 1.07, 95% CI 0.66–1.73). Findings were similar when restricted to those with CHADS-VASc ≥ 4. Conclusion: A 1-year period of home-based, twice-weekly screening for AF increased diagnoses of AF for the screening period but did not lead to increased diagnoses of AF or a reduction in cardiovascular-related events or all-cause death over a median of 4.2 years, even in those at highest risk of AF. These results suggest that benefits of regular ECG screening over a 1-year period are not maintained after cessation of the screening protocol. |
published_date |
2023-05-02T12:06:31Z |
_version_ |
1772299790386724864 |
score |
11.021648 |